1. 177Lu-DOTA-Octreotate Therapy for Neuroendocrine Tumors: A Case Report and Review of the Literature.
- Author
-
Bartseas, Georgios, Alevizopoulos, Nektarios, Skoura, Lina, Xousianakou, Eirini, Vaslamatzis, Michael, and Datseris, Ioannis
- Subjects
- *
NEUROENDOCRINE tumors , *RADIOISOTOPE therapy , *PEPTIDE receptors , *THERAPEUTICS , *TUMOR treatment - Abstract
Favorable outcomes of peptide receptor radiotherapy of neuroendocrine tumors (NET) have been reported during the recent years. A patient with a non-functional neuroendocrine pancreatic carcinoma with abdominal lymph nodes and metastatic involvement of the liver is presented. After initial chemotherapy failure, he received 4 cycles of fractionated treatment with 177Lu-DOTA-octreoate (29,6GBq), which induced an impressive improvement of patient's symptoms. We conclude that 177Lu-DOTA-octreotate fractionated therapy should be a therapeutic option for inoperable or metastasized NET patients promising symptomatic relief, and patients with large NETs expressing high somatostatin receptor density. [ABSTRACT FROM AUTHOR]
- Published
- 2016